DUBLIN–(BUSINESS WIRE)–Feb 5, 2021–
The "Homozygous Familial Hypercholesterolemia – Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com’s offering.
This ‘Homozygous familial hypercholesterolemia (HoFH) – Epidemiology Forecast – 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Homozygous familial hypercholesterolemia (HoFH) epidemiology in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
Epidemiology Perspective
The disease epidemiology covered in the report provides historical as well as forecasted epidemiology segmented by Prevalence of Homozygous Familial Hypercholesterolemia (HoFH), Diagnosed Prevalence of Homozygous Familial Hypercholesterolemia (HoFH) and Mutation-specific Distribution of Homozygous Familial Hypercholesterolemia (HoFH) in the 7MM market covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom) and Japan from 2017 to 2030.
Homozygous Familial Hypercholesterolemia (HoFH) Detailed Epidemiology Segmentation
- The prevalent population of HoFH in the seven major markets is estimated to be 3,882 in 2020.
- The diagnosed prevalent cases of HoFH in the United States are estimated to be 698 in 2020.
- HoFH can be divided into LDL Receptor (LDLR), Apolipoprotein B (Apo B), Proprotein Convertase Subtilin/Kexin 9 (PCSK9), and other rare mutations (SREBP2, and STAP1 genes, LDLRAP1 gene) based on the types of mutations causing the condition. In the United States, the number of cases of HoFH caused by LDLR, Apo B, PCSK9, and other rare mutations (SREBP2, and STAP1 genes, LDLRAP1 gene) was 587, 20, 13, and 33 respectively, in 2017.
- In the EU5 countries, the diagnosed prevalence of HoFH was maximum in Germany with 231 cases, followed by the France with 189 cases in 2017. While the least number of cases were in Spain, with 131 cases in 2017.
- In Japan, the diagnosed prevalence of HoFH is estimated to be 215 in 2020.
Report Highlights
- Eleven Years Forecast of Homozygous Familial Hypercholesterolemia (HoFH)
- 7MM Coverage
- The publisher has also analysed mutation-specific data of HoFH, which suggested that mutations in the LDLR gene is the most common causes of HoFH as compared to Apo B, PCSK9, and other rare mutations (SREBP2, and STAP1 genes, LDLRAP1 gene).
Key Questions Answered
- What is the disease risk, burden and unmet needs of Homozygous Familial Hypercholesterolemia (HoFH)?
- What is the historical Homozygous Familial Hypercholesterolemia (HoFH) patient pool in the United States, EU5 (Germany, France, Italy, Spain, and the UK) and Japan?
- What would be the forecasted patient pool of Homozygous Familial Hypercholesterolemia (HoFH) at the 7MM level?
- What will be the growth opportunities across the 7MM with respect to the patient population pertaining to Homozygous Familial Hypercholesterolemia (HoFH)?
- Out of the above-mentioned countries, which country would have the highest prevalent population of Homozygous Familial Hypercholesterolemia (HoFH) during the forecast period (2020-2030)?
- At what CAGR the population is expected to grow across the 7MM during the forecast period (2020-2030)?
Key Topics Covered:
1 Key Insights
2 EXECUTIVE SUMMARY
3 HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) OVERVIEW AT A GLANCE
3.1 PATIENT SHARE (%) DISTRIBUTION IN 2017
3.2 PATIENT SHARE (%) DISTRIBUTION IN 2030
4 DISEASE BACKGROUND AND OVERVIEW
4.1 SYMPTOMS OF HOFH
4.2 GENETICS OF HOFH
4.2.1 Genetic heterogeneity translates to phenotypic variability
4.2.2 Metabolic characteristics of HoFH
4.3 DIAGNOSIS OF HOFH
5 RECOGNIZED ESTABLISHMENTS
6 TREATMENT AND MANAGEMENT
6.1.1 Lifestyle Modifications
6.1.2 Medication
6.1.3 LDL Apheresis
6.1.4 Liver Transplantation
6.1.5 Possible future treatments for HoFH
6.1.6 Treatment for Pediatric HoFH
7 HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA: GUIDELINES BY EUROPEAN ATHEROSCLEROSIS SOCIETY (EAS) (2014)
7.1 DIAGNOSIS OF HOFH
7.1.1 Plasma low-density lipoprotein cholesterol levels
7.1.2 Xanthomas and arcus corneae
7.1.3 Family history
7.1.4 Differentiation from sitosterolemia
7.1.5 Cardiovascular complications and natural history
7.1.6 Screening for subclinical atherosclerosis
7.2 CURRENT TREATMENT FOR HOFH
7.2.1 Pharmacotherapy
7.2.2 Lipoprotein apheresis
7.2.3 Liver transplantation and other surgical approaches
7.2.4 Other issues
7.2.5 Recommendations
8 JAPAN ATHEROSCLEROSIS SOCIETY (JAS) GUIDELINES FOR PREVENTION OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASES 2017
8.1 DIAGNOSIS OF HOFH
8.1.1 Diagnostic Criteria
8.2 TREATMENT OF HOFH
8.2.1 Target Levels for Management
8.2.2 Lifestyle Modification
8.2.3 Drug Therapy
8.2.4 LDL Apheresis in HoFH
8.2.5 Pregnancy and Delivery of Patients with HoFH
8.2.6 HoFH Designated as an Intractable Disease
9 GUIDANCE FOR PEDIATRIC FAMILIAL HYPERCHOLESTEROLEMIA (2017)
9.1 DIAGNOSIS OF PEDIATRIC HOFH
9.1.1 Clinical Features of Pediatric HoFH
9.1.2 Genetic Diagnosis of HoFH
9.1.3 Important Notes for Diagnosis of HoFH
9.1.4 Differential Diagnosis
9.2 EVALUATION FOR ATHEROSCLEROTIC CARDIOVASCULAR DISEASES IN PEDIATRIC HOFH
9.2.1 Medical Questionnaire
9.2.2 Physical Findings
9.2.3 Biochemical Examination
9.2.4 Morphological Examinations
9.3 TREATMENT OF PEDIATRIC HOFH
9.3.1 Drug Therapy for Pediatric HoFH
10 TREATMENT ALGORITHM FOR HOFH
11 EPIDEMIOLOGY AND PATIENT POPULATION
11.1 KEY FINDINGS
11.2 7MM PREVALENT POPULATION OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
11.3 7MM DIAGNOSED PREVALENT POPULATION OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA
12 7MM EPIDEMIOLOGY OF HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
12.1 ASSUMPTIONS AND RATIONALE
12.2 UNITED STATES
12.2.1 Prevalence of Homozygous Familial Hypercholesterolemia (HoFH) in the United States
12.2.2 Diagnosed Prevalence of Homozygous Familial Hypercholesterolemia in the United States
12.2.3 Mutation-specific Distribution of Homozygous Familial Hypercholesterolemia in the United States
12.3 EU5 COUNTRIES
12.4 GERMANY
12.5 FRANCE
12.6 ITALY
12.7 SPAIN
12.8 UNITED KINGDOM
12.9 JAPAN
13 Appendix
For more information about this report visit https://www.researchandmarkets.com/r/blced9
View source version on businesswire.com:https://www.businesswire.com/news/home/20210204006216/en/
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Press Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
KEYWORD:
INDUSTRY KEYWORD: GENERAL HEALTH GENETICS HEALTH
SOURCE: Research and Markets
Copyright Business Wire 2021.
PUB: 02/05/2021 02:03 AM/DISC: 02/05/2021 02:03 AM
http://www.businesswire.com/news/home/20210204006216/en
